Last reviewed · How we verify

Ropivacaine and dexamethasone — Competitive Intelligence Brief

Ropivacaine and dexamethasone (Ropivacaine and dexamethasone) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic with corticosteroid adjuvant. Area: Anesthesia/Pain Management.

phase 3 Local anesthetic with corticosteroid adjuvant Voltage-gated sodium channels; glucocorticoid receptor Anesthesia/Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Ropivacaine and dexamethasone (Ropivacaine and dexamethasone) — University of Texas Southwestern Medical Center. Ropivacaine provides local anesthesia by blocking sodium channels in nerve fibers, while dexamethasone reduces inflammation and prolongs the duration of the anesthetic effect.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ropivacaine and dexamethasone TARGET Ropivacaine and dexamethasone University of Texas Southwestern Medical Center phase 3 Local anesthetic with corticosteroid adjuvant Voltage-gated sodium channels; glucocorticoid receptor
Ropivacaine + dexamethasone Ropivacaine + dexamethasone Sahiwal medical college sahiwal marketed Local anesthetic with corticosteroid adjuvant Voltage-gated sodium channels; glucocorticoid receptor
Bupivacaine and Dexamethasone Injection Bupivacaine and Dexamethasone Injection Colette Curtis MD marketed Local anesthetic with corticosteroid adjuvant Voltage-gated sodium channels (bupivacaine); glucocorticoid receptor (dexamethasone)
Bupivacaine Hydrochloride combined with dexamethasone Bupivacaine Hydrochloride combined with dexamethasone Zhejiang Cancer Hospital marketed Local anesthetic with corticosteroid adjuvant Voltage-gated sodium channels (bupivacaine); glucocorticoid receptor (dexamethasone)
Bupivacaine 0.5% , Dexamethasone Bupivacaine 0.5% , Dexamethasone Sisli Hamidiye Etfal Training and Research Hospital marketed Local anesthetic with corticosteroid adjuvant Voltage-gated sodium channels (bupivacaine); glucocorticoid receptor (dexamethasone)
Ropivacaine 0.2% + Dexamethasone Ropivacaine 0.2% + Dexamethasone Instituto do Coracao phase 3 Local anesthetic with corticosteroid adjuvant Voltage-gated sodium channels (ropivacaine); glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic with corticosteroid adjuvant class)

  1. Colette Curtis MD · 1 drug in this class
  2. Instituto do Coracao · 1 drug in this class
  3. Sahiwal medical college sahiwal · 1 drug in this class
  4. Sisli Hamidiye Etfal Training and Research Hospital · 1 drug in this class
  5. University of Texas Southwestern Medical Center · 1 drug in this class
  6. Zhejiang Cancer Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ropivacaine and dexamethasone — Competitive Intelligence Brief. https://druglandscape.com/ci/ropivacaine-and-dexamethasone. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: